Optimally, synovial samples (synovial fluid or biopsies) collected from RA patients before and after MTX treatment could validate the in vitro findings and elucidate the implications of increased IL-1 and GM-CSF expression. The gene discussed is CSF2; the disease is rheumatoid arthritis.